Using plasma proteomics to understand Alzheimer’s and other brain diseases
Using plasma proteomics to understand Alzheimer’s and other brain diseases
The plasma proteome presents a goldmine of information that can be used to develop diagnostic tests and identify novel drug targets. In this webinar, our expert speaker Dr. Keenan Walker describes his research into understanding the proteins, protein networks and biological pathways involved in age-related neurodegenerative diseases and vascular cognitive impairment.
Dr. Walker discusses how he integrates proteomic, genetic, brain imaging and cerebrospinal fluid biomarkers from initially cognitively normal individuals who later develop dementia, in order to discover novel blood-based biomarkers and mechanistically relevant proteins for therapeutic target prioritization.
Learn about:
- Proteins most strongly implicated in dementia risk
- How combining proteomics with neuroimaging to provide new insights into cerebral small vessel disease
- The process of nominating potentially casual proteins and genetically validating biomarkers
Keenan Walker, PhD
Chief, Multimodal Imaging of Neurodegenerative Disease (MIND)
National Institute on Aging
Keenan Walker, PhD, is an investigator at the National Institute on Aging Intramural Research Program and Chief of the Multimodal Imaging of Neurodegenerative Disease (MIND) unit. Dr. Walker’s current research program focuses on understanding the role of abnormal immune function in Alzheimer’s disease and late-life cognitive decline.
Using plasma proteomics to understand Alzheimer’s and other brain diseases
A presentation by Keenan Walker, PhD
More webinars
WebinarProteomics for precision neuroscience: the power of protein analysis
This webcast highlights how academic, industry and government researchers are directly measuring protein abundance and function via multiplex proteomics to build more detailed characterizations of the biological systems underlying neurodegenerative diseases.
WebinarCorrelation of a Nonalcoholic Steatohepatitis Proteomic Test with Clinical Outcomes
In this webinar, Anne Minnich, PhD, biomarker consultant at Bristol Myers Squibb, presents research on the use of the new SomaSignal(TM) NASH bundle test in a recently completed clinical trial.
WebinarHarnessing AI and proteomics for glioblastoma
The development and advancement of aptamer technology opens vast possibilities for unlocking the biocomplexity available within proteomics. Learn more about the powerful tools that are enabling the discovery and validation of clinically relevant biomarkers and accelerating research.